Actively Recruiting
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Led by Beijing Tiantan Hospital · Updated on 2026-03-27
832
Participants Needed
1
Research Sites
106 weeks
Total Duration
On this page
Sponsors
B
Beijing Tiantan Hospital
Lead Sponsor
X
Xiangya Hospital of Central South University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Postherpetic neuralgia (PHN) is the most common complication of herpes zoster (HZ) and represents a major clinical challenge due to its chronicity and impact on quality of life. Current treatments for acute HZ pain have limited efficacy in preventing PHN, highlighting the need for effective preventive strategies targeting early pathophysiological mechanisms. Venlafaxine as a plausible and clinically relevant candidate for early intervention to prevent the transition from acute HZ pain to PHN.
CONDITIONS
Official Title
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age more than 18 years
- Onset of herpes zoster rash less than 30 days ago
- Moderate to severe herpes zoster pain with an average pain score of at least 4 on a Numeric Rating Scale (0-10)
- Aspartate aminotransferase and alanine aminotransferase levels less than twice the upper limit of normal
- Estimated glomerular filtration rate of 30 mL/min per 1.73 m2 or higher
- Able and willing to sign informed consent and comply with study requirements
You will not qualify if you...
- Herpes zoster involving head, neck, eyes, mucous membranes, cranial nerves, central nervous system, or generalized herpes zoster
- Known allergy to venlafaxine
- History of major depressive disorder requiring antidepressant therapy
- History of systemic immune diseases, organ transplantation, or cancers
- Pregnant or breastfeeding
- Presence of acute or chronic pain disorders other than herpes zoster
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China
Actively Recruiting
Research Team
F
Fang Luo
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here